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Mindy S Lo1*, David Zurakowski2, Mary Beth F Son1 and Robert P Sundel1Abstract
Background: The significance of hypergammaglobulinemia as a marker of immune activation is unknown, as a
differential diagnosis for hypergammaglobulinemia in children has not been adequately established. The goal of
this study was to identify conditions associated with hypergammaglobulinemia in children, with the hypothesis that
elevated immunoglobulin levels may precede or predict the development of autoimmune conditions.
Methods: We reviewed the medical records for all children with IgG level ≥2000 mg/dL treated at a tertiary care
children’s hospital from January 1, 2000 through December 31, 2009. We compared clinical and laboratory features
of these patients, and developed an algorithm to predict the likelihood of underlying autoimmunity based on these
characteristics.
Results: After excluding children who had received IVIG, a total of 442 patients with hypergammaglobulinemia
were identified. Of these, nearly half had autoimmune conditions, most frequently systemic lupus erythematosus
and lupus-related disorders. Autoimmune gastrointestinal disorders such as inflammatory bowel disease were also
common. Infectious diseases were the next largest category of diseases, followed with much less frequency by
malignant, drug-related, and other conditions. In comparison with non-autoimmune conditions, patients with auto-
immune disease had higher IgG levels, lower white blood cell counts, lower hemoglobin values, and lower C-reactive
protein (CRP) levels. Multivariable logistic regression confirmed that CRP (P = 0.002), white blood cell count (P < 0.001),
hemoglobin (P = 0.015), and female gender (P < 0.001) are independent risk factors for autoimmune disease in patients
with high IgG levels.
Conclusions: In a cohort of pediatric patients at a tertiary care children’s hospital, hypergammaglobulinemia was most
commonly associated with autoimmune diseases. In female patients with hypergammaglobulinemia, the presence of
leukopenia, anemia, and normal CRP was 95% predictive of underlying autoimmune disease.Background
Polyclonal hypergammaglobulinemia in adult patients is
most frequently related to liver disease, malignancy,
autoimmune disease, or infection [1]. The differential
diagnosis and clinical significance of hypergammaglobu-
linemia have not been similarly well defined in children.
Malignancies and autoimmunity are much less common
in children compared to the adult population, and there-
fore the implications of an elevated immunoglobulin* Correspondence: mindy.lo@childrens.harvard.edu
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Hospital and Department of Pediatrics, Harvard Medical School, 300
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reproduction in any medium, provided the orlevel in pediatric patients may be different than in
adults. Nonetheless, in one study of children with pro-
longed fever of unknown origin, elevated gamma globu-
lin levels were associated with an ultimate diagnosis of
autoimmune disease [2]. In contrast, other more com-
mon tests such as blood counts and urinalysis were of
comparatively little value in determining the cause of a
protracted, unexplained fever.
In children with cryptogenic inflammation, the pres-
ence of hypergammaglobulinemia might have clinical
implications that hint at diagnosis and/or prognosis.
Autoimmune conditions in particular may be difficult to
diagnose in children due to their infrequency in the
pediatric population and the variability of clinicalThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nemia might aid in the diagnosis of these conditions. In
this study, we examined a cohort of patients treated at a
tertiary care children’s hospital over a 10 year period
who were found to have significantly elevated IgG levels.
We sought to determine diagnoses associated with
hypergammaglobulinemia, and to identify risk factors for
the presence of autoimmune disease.
Methods
Study group
We queried the central laboratory database at Boston
Children’s Hospital, a large tertiary care pediatric hos-
pital, for all elevated IgG results between January 1, 2000
and December 31, 2009. All inpatient and outpatient
serum IgG levels ≥2000 mg/dL were identified. This cut-
off was selected as it represents roughly two standard
deviations above the mean at our institution. A single in-
vestigator (ML) abstracted relevant information for each
patient from the electronic medical record. For patients
who had more than one test result above the 2000 mg/
dL threshold, data from the earliest encounter were
used. The study was approved by the Boston Children’s
Hospital Institutional Review Board.
Consent
As a retrospective study covering a 10 year period of
time, contacting patients to consent to medical record
review was felt to be impractical. Following data extrac-
tion, all information was de-identified to protect patient
privacy. Waiver of consent was granted by our institu-
tional review board.
Data extraction
For all subjects we recorded previously known diagnoses
at the time of the test showing an elevated IgG level,
new diagnoses made within 1 month of testing, and last
recorded diagnosis. Follow up was limited to the most
recent document available in the electronic medical
record.
Demographic information including age, sex, race/eth-
nicity, and family history was also recorded. Race and
ethnicity were based on self-identified categories from
the patient registration database. Presenting complaints,
co-morbid conditions, and, when available, additional la-
boratory data from the day on which the index IgG re-
sult was obtained, were also recorded. These values
included serum IgA, IgM and complement levels,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and complete blood counts.
Statistical analysis
Univariate analysis included Student’s t-test to compare
autoimmune and non-autoimmune cohorts for normallydistributed laboratory variables (including IgG, ESR,
white blood cell count (WBC), absolute neutrophil count
(ANC), absolute lymphocyte count (ALC), hemoglobin,
and platelet count). The Mann–Whitney U-test to com-
pare CRP values since they did not conform to a normal
distribution. Multivariable logistic regression analysis
(stepwise backward selection) was used to identify sig-
nificant independent predictors of autoimmune disease
based on variables significant in the univariate analysis
along with gender as a covariate tested in the multi-
variate model. Receiver operating characteristic (ROC)
curve analysis was applied to determine optimal cut-
off values for significant multivariable predictors [3].
Multivariable logistic regression was performed again
using the variables with the optimal cut-off values to
obtain adjusted odds ratios (OR), 95% confidence in-
tervals (CI) and likelihood ratio tests (LRT) and to
develop a predictive algorithm based on the combin-
ation of risk factors [4].
Statistical analysis was conducted using IBM SPSS Sta-
tistics (version 21.0, IBM, Armonk, NY). Two-tailed
values of P < 0.05 were considered statistically signifi-
cant. Power analysis indicated that a minimum of 150
patients with autoimmune disease and 150 with non-
autoimmune disease would provide 80% power to detect
an odds ratio of 2.0 using logistic regression analysis for
any laboratory test with the established cut-off value




A total of 26,354 patients had a documented IgG level
during the study period. There were 1519 results with
IgG ≥ 2000 mg/dL belonging to 748 individual patients.
For 8 patients, there was insufficient information in the
electronic medical record to meet inclusion criteria for
the study. Another 298 patients were excluded because
they had received IVIG within 1 month of the test result.
Among these, common reasons for receiving IVIG in-
cluded Kawasaki disease, immunodeficiency, idiopathic
thrombocytopenic purpura, autoimmune hemolytic
anemia, and juvenile dermatomyositis.
The remaining 442 patients were categorized accord-
ing to their last known primary diagnosis (Table 1). The
average age in our study group was 14.3 years (median
14.3, IQR 10.4-17.5); the majority (63%) were female. Ra-
cial background was recorded as follows: 229 (58%)
identified themselves as “white,” 81 (18%) as “black,” 31
(7%) as Hispanic, and 26 (6%) as Asian. The remaining
75 patients (17%) were identified as “other,” or no racial
information was available. The average follow-up period
for subjects was 3.48 years (median 2.92).
Table 1 Clinical characteristics of patients with hypergammaglobulinemia
Total Autoimmune Infection Malignancy PID Drug Other
n = 442 n = 221 n = 163 n = 10 n = 15 n = 9 n = 25
Median age, years 14.3 13.8 14.8 13.2 13.7 16.6 13.8
Female, n (%) 228 (63) 168 (76) 80 (49) 2 (20) 11 (73) 5 (56) 12 (48)
Race/ethnicity, n (%)
White 229 (52) 95 (43) 107 (66) 5 (50) 6 (40) 8 (89) 8 (32)
Black 81 (18) 49 (22) 24 (15) 2 (20) 0 (0) 0 (0) 7 (28)
Hispanic 31 (7) 19 (9) 9 (6) 1 (10) 0 (0) 0 (0) 2 (8)
Asian 26 (6) 13 (6) 6 (4) 1 (10) 3 (20) 0 (0) 3 (12)
Other/unknown 75 (17) 44 (20) 17 (10.6) 2 (20) 6 (40) 1 (17) 5 (20)
Median follow-up period, years 2.9 3.3 3.0 3.5 2.6 0.5 2.0
Death during follow-up period, n (%) 42 (10) 6 (3) 30 (18) 3 (30) 1 (7) 0 (0) 1 (4)
PID primary immunodeficiency.
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Primary diagnoses were divided into six categories that
have been associated with hypergammaglobulinemia in
previous reports: 1) autoimmune and autoinflammatory
diseases, 2) infections, 3) drug-associated syndromes, 4)
malignancies/lymphoproliferative disorders and hemato-
poietic stem cell transplants, 5) primary immunodeficien-
cies, and 6) other conditions not fitting these categories.
Over 60 unique diagnoses were recorded in association
with high IgG levels (Table 2).
Autoimmune and autoinflammatory diseases
The largest category of associated diagnoses was auto-
immunity (221 patients, 50%), and rheumatologic diseases
dominated this group. Systemic lupus erythematosus (SLE)
was the most common diagnosis (48 patients), followed by
mixed connective tissue disease (MCTD, 29 patients), poly-
articular juvenile idiopathic arthritis (29), systemic onset
juvenile idiopathic arthritis (15), and spondyloarthritis (11).
Vasculitis diagnoses included Takayasu arteritis, polyarteri-
tis nodosa, cutaneous vasculitis, granulomatosis with poly-
angiitis (previously known as Wegener's granulomatosis),
and eosinophilic granulomatosis with polyangiitis (previ-
ously known as Churg-Strauss syndrome). One patient had
Kawasaki disease with elevated IgG level noted prior to
IVIG treatment.
At the time that a high IgG level was first documented,
15 subjects had so-called ‘incomplete lupus,’ with fewer
than the 4 criteria necessary to meet American College
of Rheumatology criteria for a classification of SLE [6]. Pre-
senting symptoms variably included Raynaud phenome-
non, fever, fatigue, arthralgias, rash, pericarditis, and
thrombocytopenia. Median follow-up period for these pa-
tients was 3.7 years, during which time 6 of the 15
patients eventually met criteria for a rheumatologic
condition (2 each MCTD, SLE, and Sjogren syndrome).
Another patient developed hypothyroidism 5 years afterhypergammaglobulinemia was first detected. Median IgG
level when first tested was higher among patients who pro-
gressed to a full-fledged autoimmune disease compared to
those who did not, although the difference was not statisti-
cally significant (2305 mg/dL vs. 2160 mg/dL respectively;
P = 0.33). Four of the 6 patients who progressed to a specific
rheumatologic diagnosis showed increasing IgG levels over
time. In contrast, the IgG level declined over time in all pa-
tients who were not ultimately diagnosed with a rheumato-
logic disease.
A large proportion of the patients in this category had
gastrointestinal disorders (39 patients, 18%). There were 14
patients with ulcerative colitis, 10 with Crohn disease, 10
with autoimmune hepatitis, and 9 with primary sclerosing
cholangitis (PSC). Several patients had features of more
than one gastrointestinal disorder, with the most common
overlap being PSC with ulcerative colitis. Two patients
with Crohn disease also had spondyloarthropathy, while
one patient with ulcerative colitis also had chronic nonbac-
terial osteomyelitis.
Additional conditions observed in the autoimmune/
autoinflammatory cohort included anti-phospholipid
syndrome, autoimmune hemolytic anemia (AIHA), idio-
pathic thrombocytopenic purpura (ITP), acute dissemi-
nated encephalomyelitis, juvenile dermatomyositis, and
reactive arthritis. One patient had neonatal onset multi-
system inflammatory disease (NOMID), an inherited
periodic fever syndrome associated with chronic inflam-
mation. Of note, while autoimmune hematologic disease
was one of the presenting features for 2 of the patients
with partial lupus described above, several other subjects
with AIHA or ITP were ANA negative and did not de-
velop other features of SLE during the study period.
Infectious diseases
The second largest category among children with hyper-
gammaglobulinemia was infection (163 patients, 37%),
Table 2 Conditions associated with high IgG level in a pediatic cohort
Autoimmune/autoinflammatory (221) Infectious (163) Malignancy/stem cell transplantation (10)
Lupus/MCTD/SS (82) Chronic/recurrent (88) Acute lymphoblastic leukemia
Dicoid lupus Atopic dermatitis with superinfection Burkitt lymphoma
Mixed connective tissue disorder Chronic sinusitis Castleman’s disease
Systemic lupus erythematosus Chronic lung disease Chronic myelogenous leukemia
Sjogren syndrome Cystic fibrosis Hodgkin lymphoma
Arthritis (60) Suppurative (11) JMML
Polyarticular JIA Abscess GVHD after HSCT
Psoriatic arthritis Pyogenic pneumonia Neuroblastoma
Systemic onset JIA Streptococcus-associated (22)
Spondyloarthritis Acute rheumatic fever Immunodeficiency (15)
Vasculitis (12) Post-strep arthritis Autoimmune lymphoprolif. syndrome
Polyarteritis nodosa Post-strep glomerulonephritis Autoimmune polyglandular syndrome
Takayasu’s arteritis Streptococcal pneumonia Ataxia telangiectasia
Granulomatosis with polyangiitis (GPA) Streptococcal sepsis Congenial neutropenia
Eosinophilic GPA Viral Immune Activation (19) Hyper IgE syndrome
Gastrointestinal (39) CMV IgA deficiency
Autoimmune hepatitis EBV NK cell dysfunction
Crohn’s disease HIV
Ulcerative colitis Other (23) Drug-associated (9)
Primary sclerosing cholangitis Brucellosis Acute drug hypersensitivity reaction
Other Autoimmune (28) Endocarditis Drug-induced autoimmunity
Acute demyelinating encephalomyelitis Lyme disease
Autoimmune hemolytic anemia Osteomyelitis Other (25)
Anti-phospholipid syndrome Tuberculosis Cirrhosis
Idiopathic thrombocytopenic purpura Urinary tract infection Hemoglobin SS
Juvenile dermatomyositis Viral encephalitis IgA nephropathy
Kawasaki disease Liver steatosis
NOMID Lymphatic malformation
Sweet syndrome Orthostatic proteinuria
Undefined autoimmune condition Portal hypertension
Spastic cerebral palsy trisomy 21
Number of diagnoses are indicated in parentheses.
Abbreviations: JIA=juvenile idiopathic arthritis, CMV=cytomegalovirus, EBV=epstein-barr virus, JMML=juvenile myelomonocytic leukemia, GVHD=graft-vs.-host
disease, HSCT=hematopoietic stem cell transplant, NOMID=neonatal onset multisystem inflammatory disease.
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Of these, chronic or recurrent bacterial infection was the
most common (88 patients), the large majority of whom
were patients with cystic fibrosis (CF). Streptococcus-
related disorders comprised the next most common
group (22 patients), with diagnoses including acute rheum-
atic fever, post-streptococcal arthritis, post-streptococcal
glomerulonephritis, and acute streptococcal pneumonia.
Chronic viral infections were also associated with hyper-
gammaglobulinemia (19 patients); examples include hu-
man immunodeficiency virus (HIV), Epstein-Barr virus,
and human cytomegalovirus. One patient with HIV alsohad Burkitt lymphoma. Finally, 11 patients were diag-
nosed with suppurative infections, including abscess or
pyogenic pneumonia. Additional infectious diagnoses
were noted with much less frequency (Table 2).
Primary immunodeficiencies
The remaining diseases associated with hypergammaglo-
bulinemia were far less common. There were 15 patients
with primary immunodeficiencies; as noted earlier, pa-
tients receiving IVIG were excluded from this analysis.
Diagnoses included both those associated with chronic/
recurrent infection (eg. IgA deficiency), as well as those
Table 3 Univariate comparison of laboratory values for
autoimmune and non-autoimmune conditions
Variable Autoimmune Non-autoimmune P value
(n = 221) (n = 221)
IgG, mg/dL 2458 ± 680 2325 ± 476 0.018
ESR, mm/hr 63.9 ± 32.8 65.8 ± 32.8 0.675
CRP, mg/dL 0.6 (0.2-2.4) 2.6 (0.8-5.4) <0.001
WBC, × 103/uL 7.7 ± 4.1 10.7 ± 5.4 <0.001
ANC 4.9 ± 3.3 7.1 ± 4.6 <0.001
ALC 1.9 ± 1.1 2.6 ± 1.7 <0.001
Hemoglobin, mg/dL 11.0 ± 1.7 11.8 ± 2.0 <0.001
Platelets, × 103/μL 359 ± 195 371 ± 150 0.529
Data are mean ± SD, except CRP, which is median (interquartile range).
Table 4 Significant independent multivariable risk factors
of autoimmune/autoinflammatory disease
Risk factor Odds ratio 95% CI LRT P value
HgB < 10 mg/dL 2.1 1.2 – 3.8 5.96 0.015
WBC < 5 ×103/μL 3.9 1.9 – 8.0 16.32 <0.001
CRP < 0.5 mg/dL 2.3 1.4 – 3.8 9.81 0.002
Female gender 3.0 1.8 – 4.8 18.45 <0.001
Abbreviations: CI confidence interval, LRT likelihood ratio test.
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autoimmune polyglandular syndrome).
Malignancies/lymphoproliferative diseases and
hematopoietic stem cell transplants
Six patients were diagnosed with malignancies or lym-
phoproliferative diseases. Of these, two patients were ini-
tially evaluated in rheumatology clinic for unexplained
inflammation before their oncologic diagnoses were
confirmed.
An additional 4 patients had undergone hematopoietic
stem cell transplantation; indications included acute
lymphoblastic leukemia, chronic myelogenous leukemia,
hemophagocytic lymphohistiocytosis, and neuroblast-
oma. In some cases the hypergammaglobulinemia was
attributed by providers to graft-versus-host disease,
while in others the source was not determined.
Drug reactions
Acute drug hypersensitivity reactions were associated
with hypergammaglobulinemia in 2 patients (one each
due to carbamazepine and minocycline). Another 7 pa-
tients had chronic drug-related autoimmunity, of which
almost all were related to minocycline exposure.
Non-classifiable diagnoses
Twenty-five patients (6%) did not fit any of the above
categories. Five of these patients had primary liver dys-
function unrelated to autoimmunity. For the others,
however, there was no clear explanation for their ele-
vated gamma globulin levels. These patients included
both healthy children as well as those with medical
problems not clearly related to immune activation. This
latter group included patients with hemoglobinopa-
thies, trisomy 21, and spastic cerebral palsy without
known genetic diagnoses. None of these patients had
a history of frequent infections as detailed in the
medical record, although chronic or subacute infec-
tions could not be ruled out. Reasons for checking
IgG levels in these patients varied but included fever,
fatigue, and elevated ESR.
Risk of autoimmunity in patients with
hypergammaglobulinemia
As nearly half of the patients in our cohort had under-
lying autoimmune conditions, we sought to define pre-
dictive risk factors for the presence of autoimmunity in
patients with hypergammaglobulinemia. Univariate ana-
lyses showed that patients with autoimmune conditions
had higher IgG levels but also lower white blood cell
counts (WBC) and hemoglobin (Hgb), hematocrit, com-
plement and CRP levels (Table 3). ROC analysis with the
Youden index was applied to determine the optimal
values for identifying patients most likely to haveautoimmune causes of their hypergammaglobulinemia.
Values of <5 mg/dL (50 mg/L) for CRP, <10 mg/dL
(100 mg/L) for Hgb, and <5 × 103/μL (5 × 109/L) for
WBC were identified. Based on these demarcations,
multivariable stepwise logistic regression modeling con-
firmed that all three were highly significant independent
predictors of autoimmune disease, along with female
gender (Table 4). The odds ratios and 95% CIs provide
measures of risk for each significant predictor in the
multivariable model. To provide a clinically meaningful
assessment of risk, these variables were modeled in com-
bination to develop a predictive algorithm for estimating
the probability of an autoimmune disease stratified by
gender (Table 5). Each combination of laboratory tests
using the optimal cut-off values is included to highlight
the risk stratification for each gender. Among female pa-
tients with hypergammaglobulinemia, the presence of
anemia, leukopenia, and normal CRP values together
was 95% predictive for the presence of autoimmune
disease.
Discussion
We present here the largest study of children with ele-
vated serum levels of IgG. To our knowledge, this is the
first attempt to compile an inclusive differential diagno-
sis for hypergammaglobulinemia in the pediatric popula-
tion. The vast majority (almost 95%) of patients in our
study had identifiable disorders that could explain their
hypergammaglobulinemia, and these conditions could be
Table 5 Predictive algorithm for the probability of autoimmune/autoinflammatory disease based on combinations of
independent risk factors, stratified by gender
Probability of autoimmune/autoinflammatory disease
HGB < 10 mg/dL WBC < 5 ×103/μL CRP < 0.5 mg/dL Female Male
- - - 48% 24%
+ - - 66% 40%
- - + 68% 42%
- + - 79% 56%
- + + 82% 60%
+ + - 88% 72%
+ - + 90% 74%
+ + + 95% 86%
Probabilities were determined by multivariable logistic regression analysis.
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autoimmune/autoinflammatory disorders were by far the
most common.
Hypergammaglobulinemia is well-recognized as a key
feature of SLE and lupus-related conditions [7]. The dif-
fuse B cell activation and autoantibody production that
is characteristic of SLE is also central to disease patho-
genesis. Both MCTD and Sjogren’s syndrome are
thought to have related pathogenic mechanisms. SLE
and MCTD were the most common diseases observed
in this study, representing 17% of the children with
hypergammaglobulinemia. While other rheumatologic
conditions, such as forms of juvenile arthritis, were also
diagnosed relatively frequently, the number with SLE
and MCTD was disproportionate to the overall preva-
lence of these disorders in the pediatric population (ap-
proximately 3–12 per 100,000, less than 1/4 of the
prevalence of juvenile arthritis [8,9]). Autoimmune con-
ditions of the gastrointestinal tract were also common,
in particular inflammatory bowel disease and auto-
immune hepatitis.
The infectious conditions associated with high IgG
levels also fell into distinct categories. Chronic respira-
tory infections, such as those seen in patients with CF,
were the most common infection associated with high
IgG levels. Hypergammaglobulinemia was first noted in
CF patients almost 40 years ago [10], and IgG levels cor-
relate with disease progression [11,12]. Streptococcal-
associated conditions were also common in our cohort,
particularly non-suppurative complications of strepto-
coccal infection (rheumatic fever, post-streptococcal
glomerulonephritis, and post-streptococcal arthritis).
Hypergammaglobulinemia has long been noted in pa-
tients with acute rheumatic fever, and was described at
almost the same time that IgG was first characterized
[13]. While IgG levels do not seem to correlate with se-
verity of disease, hypergammaglobulinemia may help
distinguish active rheumatic fever from inactiverheumatic heart disease [14]. The reason for the
uniquely potent serologic response to streptococcal in-
fections is unclear, though streptococcus has a propensity
for causing a wide variety of post-infectious sequelae.
Among these, Henoch-Schonlein purpura and polyarteri-
tis nodosum were identified only rarely in the present
cohort.
Gammopathy, both monoclonal and polyclonal, has
been described in adults with a variety of chronic liver
conditions [15-17]. In our pediatric cohort, liver disease
was a relatively rare association with hypergammaglobu-
linemia, even when including patients with autoimmune
and infectious hepatitis. High IgG levels in the context
of autoimmune and infectious liver conditions may re-
flect chronic immune activation, but the mechanism by
which primary liver dysfunction leads to gammopathy in
the absence of systemic inflammation is not known.
Other factors related to the aging process, or accumu-
lated exposures over time, may explain the discrepancy
in the incidence of liver disease among adults and chil-
dren with hypergammaglobulinemia.
There were only a few patients with malignant condi-
tions in our cohort; all had lymphoproliferative disor-
ders. Two of these had presented to rheumatologists
prior to their oncologic diagnosis. The first, a 14 year
old girl, had initially been diagnosed with viral arthritis.
Additional clinical findings one year later led to the
diagnosis of Hodgkin’s lymphoma. The second patient
was a 17 year old with multiple physical examination
and laboratory criteria consistent with MCTD. However,
he was also found to have extensive lymphadenopathy
and hepatomegaly. Further evaluation ultimately re-
vealed Burkitt lymphoma. Due to the small number of
proliferative disorders in our cohort, we are unable
to speculate whether lymphocyte dysregulation led to
both hypergammaglobulinemia and development of the
malignancy, nor can we identify risk factors for distin-
guishing autoimmune from malignant conditions. In
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of hypergammaglobulinemia in children.
Given the prevalence of autoimmune conditions in
our pediatric cohort with hypergammaglobulinemia, we
developed a predictive algorithm for identifying patients
who are at increased risk for autoimmunity. We antici-
pate that this algorithm may be useful in the evaluation
of children with unexplained systemic inflammation,
since children with hypergammaglobulinemia are most
likely to be incidentally identified on the basis of an ele-
vated ESR. While elevated fibrinogen levels cause a high
ESR in children with actual inflammation [18], high im-
munoglobulin levels can also contribute to elevation of
the ESR in those with HIV, SLE, and other conditions
identified among our study subjects. In such patients,
the presence of a low white blood cell count, low
hemoglobin, low CRP and female gender should increase
concern for a possible autoimmune disease.
Hypergammaglobulinemia in patients with auto-
immune/autoinflammatory disorders is multifactorial in
etiology. Polyclonal B cell activation is well known to
play a prominent role in SLE and other conditions char-
acterized by autoantibodies [19]. Multiple cytokines in-
fluence this B cell activation. For example, B cell
activating factor (BAFF) and IL-6 are elevated in SLE
and other autoimmune diseases [20]. Interestingly, IL-6
has pleiotropic pro-inflammatory effects that also play a
role in the pathogenesis of autoinflammatory conditions
[21,22]. It is not clear how B cells influence autoinflam-
matory disorders such as NOMID and Crohn disease;
one possibility may be that B cell activation and antibody
production in these conditions are bystander effects of
IL-6 activity.
A significant limitation of this study is the potential
bias among children in whom a decision was made to
measure immunoglobulin levels. Rheumatologists and
immunologists are more likely to check immunoglobulin
levels than other specialists, and thus patients with rheu-
matologic and immunologic disorders are probably over-
represented in our cohort. On the other hand, studies of
hypergammaglobulinemia in adults, and previous case
series in children, do not suggest that large numbers of
children who have other illnesses or who are entirely well
are likely to have IgG levels above 2000 mg/dL. Nonethe-
less, as our predictive algorithm was developed from this
potentially skewed population, it will require prospective
testing before its general applicability can be confirmed.
Conclusions
Significant hypergammaglobulinemia is relatively un-
common among children, with fewer than 500 patients
identified with non-iatrogenic IgG levels over 2000 mg/
dl at a large, tertiary care children’s hospital over the
course of a decade. A significant number of thesechildren were diagnosed with a relatively limited number
of serious but treatable conditions. Though the differen-
tial diagnosis of a serum IgG level above 2000 mg/dl in
children is similar to that described in adults, there are
important differences. In particular, autoimmunity is sig-
nificantly more highly represented, while liver disease
and malignancy are relatively infrequent causes of high
IgG levels in children. There should be a high index
of suspicion for underlying autoimmune disease in
pediatric patients with high IgG levels and no clear in-
fectious or malignant process. This risk of an auto-
immune disease may be further quantified on the
basis of gender, white blood cell count, hemoglobin
level and CRP.
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